BioSpace News Archive

There are a few lessons from the pandemic about the work which everyone should learn to be more productive. We have compiled the list of them. So let’s take a look.

The U.S. Food and Drug Administration approved Merck and Bayer’s heart failure drug vericiguat, an orally administered soluble guanylate cyclase (sGC) stimulator, the pharma giants announced this morning.

Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

A brief rundown of the biopharmas that brought in the cash the past week.

Rochelle Walensky, who most recently served as chief of the division of infectious diseases at Massachusetts General Hospital, will become the new head of the U.S. Centers for Disease Control and Prevention under the administration of Joe Biden.

NEUVOGEN’s official strategy revolves around covering the entire immune system so that the tumor cannot perform an “immune escape”. Past immune priming efforts have fallen short because they focus on only a handful of important targets that some tumor cells may not express, thereby allowing them to escape the therapy’s boundaries.

Precision medicine developer Kura Oncology is positioned to make a meaningful difference in the treatment of cancer in the next few years with its two, wholly-owned, small molecule compounds.

Last year was a record number of IPOs in the biotech industry, with 81 raising $13.5 billion. With this kind of a start, 2021 may be scorching.

A naturally occurring system for tuning CRISPR-Cas9 expressing in bacteria, identified in a study published in Cell, could have implications for gene editing therapies as well.

Pfizer and BioNTech announced that their COVID-19 vaccine was probably just as effective against the variant strain of the virus, B.1.1.7, found in the U.K.